Status: Recruiting
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: EpiDestiny, Inc.Updated: Sep 30, 2026Locations: 1
Eligibility criteria
Age 18 years or older. [+6]
Inability to give informed consent. [+19]